In vitro 'time-to-kill' assay to assess the cidal activity dynamics of current reference drugs against Leishmania donovani and Leishmania infantum

scientific article published on 5 October 2016

In vitro 'time-to-kill' assay to assess the cidal activity dynamics of current reference drugs against Leishmania donovani and Leishmania infantum is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/JAC/DKW409
P698PubMed publication ID27707992

P50authorSarah HendrickxQ94593639
P2093author name stringE Eberhardt
L Maes
G Caljon
J Beyers
A Mondelaers
M Van den Kerkhof
P2860cites workExperimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocolQ28483977
Leishmania donovani develops resistance to drug combinationsQ28484463
ParomomycinQ34864208
An update on pharmacotherapy for leishmaniasisQ34945204
Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challengesQ34953705
Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patientsQ35095252
Use of antimony in the treatment of leishmaniasis: current status and future directionsQ35377767
In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugsQ36450807
A Replicative In Vitro Assay for Drug Discovery against Leishmania donovaniQ36933516
Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovaniQ37712969
In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependentQ39444290
In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differencesQ41844113
Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.Q46191825
Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantumQ46921246
Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum.Q53541333
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectLeishmania donovaniQ1950752
Leishmania infantumQ1950789
P304page(s)428-430
P577publication date2016-10-05
P1433published inJournal of Antimicrobial ChemotherapyQ6294770
P1476titleIn vitro 'time-to-kill' assay to assess the cidal activity dynamics of current reference drugs against Leishmania donovani and Leishmania infantum
P478volume72

Reverse relations

cites work (P2860)
Q57190987Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis
Q88552967Fragment-Based Phenotypic Lead Discovery: Cell-Based Assay to Target Leishmaniasis
Q50051086In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series.
Q52673716Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.
Q89719497Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity

Search more.